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Abstract
Although respiratory syncytial virus (RSV) was discovered > 40 years ago, treatment remains
largely supportive. There are no safe and effective vaccines or specific treatments other than
prophylaxis with passive antibody therapy (palivizumab). However, there are good reasons to
think that the scene may soon change. As the pace of development of anti-viral drugs accelerates
and optimism over vaccines increases, novel therapies are set to make a major impact in the
management of this very common infection. The use and effect of such interventions are not easy
to anticipate, but could ultimately include the interruption of RSV's transmission resulting in
profound changes to the impact of RSV on human health.
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1. Background
Respiratory syncytial virus (RSV) is a common cold agent and the chief worldwide viral
cause of moderate-to-severe acute upper and lower respiratory tract illness in infancy.
Almost all children are infected by 3 years of age [1,2], most suffering only mild symptoms
with rhinorrhea, cough, fever and sometimes wheeze generally resolving in < 2 weeks.
However, 25 – 40% of children develop lower respiratory signs indicative of a viral
bronchiolitis or pneumonia. In most wealthy, temperate regions, ~ 1 in 40 infants is
hospitalised because of RSV infection.
In the US, in 2000, it was estimated that there were ~ 86,000 RSV-related hospitalisations in
a year, ~ 98% of which occurred in children < 5 years old [3].
A recently published study shows that RSV is associated with 20% of hospitalisations, 18%
of emergency department visits and 15% of office visits for acute respiratory infections from
November through April. Average annual hospitalisation rates were 17 per 1,000 children <
6 months of age and 3 per 1,000 children < 5 years of age [4]. The direct medical costs for
all RSV infection-related hospitalisations for this age group are estimated at $US394 million
in 1 year [3]; European figures are probably similar.
The risk of severe RSV infection is increased by premature birth, low birth weight or ‘small
for dates’, male gender, large family size, exposure to passive smoke, lack of breast feeding
and by birth ~ 4 months before the peak of the RSV season [5]. Pre-existing diseases
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(trisomy 21, congenital heart disease, pulmonary hypertension or immunodeficiency) and
chronic pulmonary disease (especially bronchopulmonary dysplasia) pose extra risk. In
countries with well-funded medical services, very few otherwise healthy children die of
RSV disease. However, children who suffer from severe RSV infections in infancy are
prone to recurrent wheezing and asthma diagnosis later in childhood [6] and prevention of
RSV infection in the first year of life might possibly reduce the frequency of postviral
wheeze in later life [7].
In elderly persons, RSV causes pneumonia, exacerbations of chronic obstructive pulmonary
disease (COPD) [8] and acute deterioration in those with cardiac disease, and contributes
substantially to excess deaths in the winter season. In the US, there are an estimated 14,000
– 60,000 RSV-related hospitalisations and 1,500 – 7,000 deaths in people > 65 years owing
to RSV infection each year [9,10].
1.1 Animal infection
Many vertebrate species suffer from RSV disease. Bovine RSV is a significant veterinary
problem, and both sheep and goats have their own strains of RSV. These do not transmit to
or from man.
Mice and cotton rats are the most commonly used small animal models for anti-viral studies.
Typically, anti-viral compounds or vaccines are administered before or after intranasal RSV
infection with human RSV and the assessment of viral load and lung pathology is performed
on day 4 and/or day 8 of infection. A variety of treatment regimes can be tested to define the
best dosing option.
The cotton rat model is semi-permissive for infection with human RSV strains, but infection
does not induce significant clinical signs. The virus is inoculated intranasally and viral load
and pathology is tested in the lungs and upper airways. Infected cotton rats develop
histological bronchiolitis and focal pneumonia. Mice require a relatively high dose of human
virus to become infected, but do support viral replication in the lung and nose. By careful
selection of viral strain and batch, it is possible to induce moderate-to-severe dose-related
disease in mice and to reproduce virtually all the features seen after human infection
(including pulmonary neutrophilia [11], bronchiolitis, lung function abnormalities and
specific immune responses [12]). The fact that mice are amenable to genetic manipulation,
the availability of a very wide range of reagents, relative economy and ease of handling
make mice the species of first choice in many laboratories.
Other animals used for testing RSV infection include African green and Rhesus monkeys.
Chimpanzees are very susceptible to infection with human strains of RSV and may
exchange RSV infections from animal handlers. However, ethical concerns and high costs
limit the utility of non-human primates for studies of RSV infection.
It is remarkable that all these animal species show broadly parallel augmented disease if
they are vaccinated with formalin-inactivated RSV before nasal challenge.
2. Medical need
All attempts to develop safe and effective vaccine for human use have so far been
unsuccessful. Formalin-inactivated vaccines tested in the US in 1960s failed to protect
children against the disease and, in younger infants, tended to enhance disease during
subsequent natural infection [13]. Live attenuated vaccines are being developed for human
use, but tend to induce weak immunity or revert to virulence in young children. At present,
palivizumab (a humanised mouse monoclonal antibody against the RSV fusion protein) is
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licensed for preventive use, and ribavirin has been used to treat severe infections despite
limited evidence of benefit. There is a clearly and urgent need for both vaccines and
effective antiviral drugs, but the needs may be tailored to specific groups (Table 1).
3. Scientific rationale
Drugs that interfere with virus attachment, fusion or intracellular replication can inhibit
infection. Anti-RSV antibodies interfere with the viral lifecycle by binding free virus
(neutralising antibody), attachment to host cell (antibodies to membrane-bound and secreted
forms of attachment or G protein), virus–cell and cell–cell fusion (anti-RSV F Ab),
inhibiting nucleoprotein (anti-RSV N Ab) or possibly by inhibiting the biological function
of secreted surface glycoprotein G (anti-RSV G Ab). Two main groups of the virus, RSV-A
and RSV-B, are 67% homologous at the level of nucleotides and 53% homologous at the
amino acid sequence of the G protein [14,15].
The mechanism of RSV entry to a cell is not fully defined but it is thought that RSV infects
by binding of fusion (F) protein to TLR4 receptor and that the G protein can act as a
fractalkine receptor agonist mediating immune cell chemotaxis [16]. The G protein is not
required for viral entry as recombinant viruses lacking the G protein remain infectious. After
binding, the viral wall and cell membranes fuse, an effect mediated by F protein; the
nucleocapsid complex then enters into the cytoplasm. The F protein is highly conserved
between strains (79% nucleotide and 89% amino acid homology) [15] and anti-F antibody
induced by primary RSV infection is cross-reactive between group A and B virus.
Antibodies against the G protein are highly group and even subgroup specific [17,18]. The
discovery of further receptors for RSV binding and uptake would be an important advance.
Various small molecules may interfere with the process of fusion and several inhibitors of
fusion (for instance, benzimidazole drugs such as BMS-433771 or TMC353121) are under
development. At a different level, inside a cell, viral RNA can be targeted by small
interfering RNAs (siRNAs) that prevent viral protein synthesis [19] or molecules that inhibit
function of key enzymes that may also be involved in replication and assembly of other
viruses in addition to RSV. A good example is VX-497, an inosine monophosphate
dehydrogenase (IMPDH) inhibitor, developed originally and tested in clinical trials for the
HBV treatment but with broad anti-viral activity [20].
There is also evidence that RSV may cause persistent infection. Persistence has been
demonstrated in guinea pigs [21], cows [22] and mice [23]. Persistent year-round RSV
detection in patients with COPD is associated with airway inflammation and accelerated
decline in FEV1. Those with chronic RSV infections may, therefore, benefit from anti-viral
drugs able to eliminate persistence, and, therefore, alter the natural history of COPD [24]. In
addition, drugs able to eliminate sources of RSV outbreaks in the community could
potentially contribute to limiting the prevalence of RSV in young children.
RSV infection triggers an intense host immune response that is responsible for many of the
clinical features of disease. Most viral infections induce ‘T helper 1’ type responses,
characterised by high levels of IFNγ production; by contrast, asthma and atopy are
characterised by ‘T helper 2’ cells producing IL-4 and IL-5 (Th2 cells). In animal models,
both these patterns of cytokine production are evident depending on the conditions and
previous vaccination status [12,25,26]. As it is not possible to access human samples and
perform detailed, sequential, timed analysis of the relevant cells and body fluids, the extent
to which human infection is mirrored by animal studies is difficult to judge. This issue is
highlighted by the finding that infants with severe infections sequester RSV-specific cells in
affected tissues, so that relevant cells are depleted from the peripheral blood [27].
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Samples from RSV-infected children show elevated IL-4/IFNγ ratios in infants during the
first week of acute bronchiolitis compared with infants with upper respiratory tract signs
alone [28], consistent with excessive type 2 and/or deficient type 1 immune responses in
RSV bronchiolitis [29]. In mice, RSV infection is associated with an increase in gamma-
delta T cells that make a range of cytokines, and depletion of these cells greatly attenuates
disease [30]. In man, RSV infection has been reported to be associated with reduced IFN-
gamma production by gamma-delta T cells, compared to a control group infected with
rotavirus [31].
Studies of genetic polymorphisms indicate that innate responses may be especially important
in explaining the variation in severity of RSV disease [32]. In mice, macrophages play a key
role in the early response to RSV infection [33]. In human cells, they have been reported to
upregulate Toll-like receptor 3 and 4 expression [34,35], hence promoting sensitivity to
bacterial endotoxin and other TLR4 ligands. The fact that common TLR4 polymorphisms
show a significant association with RSV bronchiolitis [36], and that TLR4 expression on
cells in the peripheral blood increases during bronchiolitis [37] suggests that this effect may
be of considerable pathogenic significance.
IL-8 may also be important as IL-8 haplotype is closely associated with RSV disease-
susceptibility [38]. Bont et al. found reduced peripheral lymphocyte function in children
with severe disease, associated with raised plasma IL-8 levels [39]. IL-8 is a chemokine that
promotes neutrophil chemotaxis and survival, and neutrophils are the predominant cell type
present in the bronchial secretions of children with severe bronchiolitis [40], and the amount
of IL-8 mRNA in the nasal aspirates of infants with bronchiolitis correlates with severity of
disease [41]. CXC chemokines (including IL-8 and IP-10) are also found in large quantities
in the lower airways of infants with severe RSV bronchiolitis [40].
IL-9 has been found in high concentrations in the airways of infants with severe
bronchiolitis [42]. IL-9 is known to induce mucus production by bronchial epithelial cells,
cause goblet cell hyperplasia and induce chemokine secretion by respiratory epithelial cells
and neutrophils, suggesting that it may have a critical role in the inflammatory cascade in
the airways during acute bronchiolitis.
The close involvement of the host immune response in the pathogenesis of RSV disease
suggests that it might be possible to modify disease with anti-inflammatory or
immunoinhibitory drugs. However, any attempt to limit the immune response would have to
be accompanied by treatment with highly effective antiviral drugs so as to prevent rebound
of viral replication. Despite many trials of steroid therapy, there is no clear benefit.
Inhibition of other inflammatory pathways should be tested once potent antiviral drugs are
available.
4. Existing treatments
Antibodies play several roles in antiviral immunity (interference with pathogen binding,
opsonisation, neutralisation and elimination), thus making them attractive therapeutic
agents. An initial prophylactic polyclonal RSV hyperimmune globulin (RespiGam, RSV-
IGIV, MedImmune) now been superseded by Synagis® (palivizumab, MedImmune,
Gaithersburg, MD, US), a humanised monoclonal Ab against RSV F protein [43,44], the
only licensed prophylactic drug for RSV at present. It is administered at 15mg/kg/month
i.m. during the RSV season (five doses). Palivizumab acts by preventing the spread of virus
to the lower respiratory tract, thus preventing the clinical manifestations of bronchiolitis.
Clinical studies showed a relative reduction in RSV-related hospital admissions of 55% in
premature infants and/or bronchopulmonary dysplasia/chronic lung disease and by 45% in
infants with hemodynamically significant congenital heart disease [45]. It has no significant
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adverse effects and there is no evidence of antibody-mediated disease enhancement [45,46].
Delaying RSV infection beyond the first year of life by prophylaxis with palivizumab may
reduce the frequency of recurrent wheeze in later childhood [47]. The high cost of Synagis
limits its use in many settings [48], and it is clear that even if it were widely used to prevent
infection in all high-risk children, the general incidence of severe disease would be little
affected, as many cases occur in otherwise normal children.
Ribavirin (1-β-d-ribofuranosyl-1,2,4-triazole-3- carboxamide, Virazole®, ICN
Pharmaceuticals Ltd, Basingstoke, UK) is a nucleoside analogue and represents the only
licensed anti-viral drug for treating RSV infection. It inhibits IMPDH, reducing formation of
mRNA and viral polymerase [49]. It is administered in aerosol form to seriously ill infants
with severe bronchiolitis and immunocompromised patients but has a limited use owing to
variable efficacy and the risk of toxicity [50-53] and high cost [54]. Drug-resistant mutants
have been reported, a significant risk with most single anti-viral agents [54-56].
5. Therapeutic class review
5.1 Fusion inhibitors
BMS-433771 inhibits the entry of the virus into cells through direct interaction with the F
protein. It works by disruption of the conformation within the fusion hairpin structure, which
is absolutely critical for the fusion [57,58]. In vitro, BMS-433771 inhibited both RSV-A and
-B replication, and had an ED50 of 20 nM. In mouse and cotton rat models of RSV infection,
BMS-433771 5 and 50mg/kg administered p.o., reduced viral lung titres [59,60]. Bristol-
Myers Squibb has discontinued further development of this compound [61].
RFI-641 is a specific inhibitor of RSV fusion. It both blocks viral fusion to the cell
membrane and prevents syncytium formation by binding to protein F [62]. In murine models
of RSV infection, RFI-641 administered nasally 2 h before infection reduced viral titres in
the lung by 0.63 – 1.53 log [63] and in African green monkeys, in nasal and throat samples
by 2.1 and 3.1 log, respectively. In the same model, it was also effective 24 h post-infection
[64]. It was tested in Phase I and II clinical trials in 2000 – 2001 [49] but Wyeth has
discontinued development of RFI-641 [61].
VP-14637 is a small molecule that inhibits RSV entry into host cells designed for inhalation
that could have been delivered directly to the infection site. The technology was suited for
use in infants and was under development by ViroPharma. VP-14637 bound specifically to
RSV-infected cells and interacted with the RSV F protein [65]. The drug was tested in an
inhaled formulation in Phase I trials to evaluate the safety and pharmacokinetic profile.
However, ViroPharma has discontinued development of this compound for strategic reasons
[61].
JNJ-2408068 is a benzimidazole derivative [66] and has a very potent anti-RSV activity. It
inhibits both virus–cell fusion and cell–cell fusion [67] of human RSV-A and -B as well as
bovine RSV but it does not work against other Paramyxoviridae. In vitro cytotoxicity and
antiviral effects are seen in the cotton rats, where selective anti-viral activity is evident.
Significant drug levels occur in the lung and a concentration of 10 nM reduces RSV load
1,000-fold. Outside the lung, only low levels of JNJ-2408068 are found [68]. In addition, it
reduces release of proinflammatory cytokines IL-6, IL-8 and RANTES from RSV-infected
A549 cells [67]. TMC353121, the new morpholinopropylaminobenzimidazole derivative of
JNJ-2408068 [69], has recently been synthesised as a result of molecular modelling in a lead
optimisation program. A process that led to the selection of TMC353121 has been described
in detail by Bonfanti et al. [69]. TMC353121 is under active preclinical evaluation by
Tibotec.
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5.2 Attachment inhibitor
MBX-300 (Microbiotix, Worcester, MA, US) is the compound that targets the attachment
protein [70] designed for the oral treatment of RSV. It underwent in vivo efficacy studies
and toxicology trials including testing in Cynomolgus monkeys and showed anti-RSV
activity and a good safety profile [70,71].
5.3 IMPDH inhibitors
EICAR is a nucleoside analogue with anti-viral properties. In vitro, it inhibits replication of
paramyxoviruses (parainfluenza, mumps, measles and RSV) and orthomyxovirus (influenza)
with EC50s of 0.06 – 2.3 μg/ml. In HeLa, Vero, MDCK and LLCMK2 cells, even doses of
200 μg/ml are non-cytotoxic. In replicating cells, 5.6 – 12 μg/ml inhibits growth. It works
by inhibiting IMPDH, leading to depletion of intracellular GTP [72]. Asahi Kasei Pharma
has discontinued development of EICAR [61].
5.4 Anti-RSV morpholino oligomers
Lai et al. [73] report the effects of two antisense phosphorodiamidate morpholino oligomers
(PMOs) targeting the sequence of RSV L mRNA, coupled to arginine-rich cell-penetrating
peptide. Phosphorodiamidate morpholino oligomers have the same nucleobases as DNA, but
a morpholine ring replaces the deoxyribose sugar and a phosphorodiamidate linkage
replaces the phosphodiester [74]. Phosphorodiamidate morpholino oligomers bind the
complementary RNA sequence and, therefore, have an antisense effect through steric
blockage of RNA [75]. Both in vitro and in vivo, the constructs can easily enter cells where
they interfere with viral protein expression. Minimal cytotoxicity was observed in human
cell lines and reduction of viral titres was significant (> 2.0 log10). Intranasal treatment of
BALB/c mice with peptide-bound PMO before the RSV inoculation produced a reduction in
viral titre of 1.2 log10 in lung tissue at day 5 post-infection, and attenuated pulmonary
inflammation at day 7 post-infection.
Collectively, these data indicate that PMOs possess potent anti-RSV activity. This strategy
is worthy of further investigation as a candidate for potential therapeutic application.
6. Competitive environment
Several promising anti-RSV compounds described earlier have been at various stages of
development (Table 2); however, many of the projects have been discontinued and at the
moment only two are in Phase II clinical trials: ALN-RSV01 and RSV-604.
6.1 Antisense anti-RSV agents: ALN-RSV01
RNA interference (RNAi) is a natural process that occurs in cytoplasm and leads to
degradation of mRNA. Small interfering RNAs are synthesised to target any endogenous
mRNA sequence in a cell or an exogenous sequence carried by a virus. While in a cell,
siRNAs incorporate into a cytoplasmic protein complex, the RNA induced silencing
complex (RISC). The antisense strand of the siRNA binds in a sequence-specific manner to
existing mRNAs in the cytoplasm, which leads to cleavage and subsequent release of the
inactivated fragments of the complementary mRNA. This process interrupts the synthesis of
the corresponding protein [19,76,77].
There have been several recent reports describing a number of antiviral siRNAs tested in
vitro and in vivo and where viral infections or cancers have been targeted by antisense-
mediated approaches [78-80]. ALN-RSV01 (Alnylam Pharmaceuticals) is the first siRNA
targeting a microbial pathogen tested in humans and the first siRNA administered to the
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human respiratory tract. ALN-RSV01 is designed to inhibit the replication of RSV by
interrupting the synthesis of the viral nucleocapsid protein (N-protein).
Studies in mice showed that ALN-RSV01 (2 mg/kg, single dose) protected against
subsequent RSV infection, and could also be used to treat an existing RSV infection, thereby
decreasing viral load > 10,000-fold [81]. The results of the first two placebo-controlled
healthy volunteer studies have just been released [77], demonstrating the drug is safe over a
wide range after nasal delivery. Further multinational, randomised, double-blind, placebo-
controlled, multidose Phase II trials with an inhaled nebuliser formulation (the expected
final route of administration) are continuing. These studies may provide validation of the
general strategy of siRNA delivery to the respiratory tract, regardless of the utility of this
approach to treatment of RSV disease.
Antisense strategies, therefore, show great promise, but may require further improvement
before they can be used clinically. Reduced cost, increased in vivo stability, increased
expression levels and delivery to relevant cell populations may all represent significant
hurdles for the development of this technology.
6.2 N protein inhibitors: RSV-604
RSV-604 is an oral benzodiazepine under development by Arrow Therapeutics (Novartis)
[82]. Found by screening libraries of small molecules, it inhibits viral replication and the
inhibitory activity is in the submicromolar range for both RSV-A and RSV-B [60]. RSV-604
represents the first in a new class of RSV inhibitors and has potential as a treatment for RSV
infection. Promising preclinical data have enabled the study of the drug in Phase I trials,
where volunteers have been exposed to increasing quantities of it. These studies showed that
the drug was well absorbed in humans, and that one dose a day was sufficient to achieve
antiviral EC90 levels [83]. It is possible that similar molecules with advantageous
pharmacokinetics will be found by molecular modification.
7. Current research goals
Although generally successful, palivizumab does not always produce perfect protection and
does not adequately protect from upper airway infection. To improve on palivizumab,
Medimmune had developed antibodies with better binding, among them motavizumab
(MEDI-524, formerly known as Numax®, Gaithersburg, MD, USA). This has 70-fold
greater binding affinity to RSV F protein in vitro and a 20-fold improvement in
neutralisation [44]. It not only inhibits RSV replication in lower respiratory tract, but also
inhibits nasal replication. In cotton rats, it causes 100-fold greater reduction in pulmonary
RSV titres compared with palivizumab [84]; in the mouse, prophylactic administration of
motavizumab significantly reduces RSV replication and reduces local and systemic levels of
TNF-α, IL-1α, IL-12p70, KC, IL-10 and IFNγ [85].
Motavizumab has now been tested in Phase III clinical trials in 6,635 pre-term infants at
high risk of RSV infection. Its use was associated with significantly fewer hospitalisations
compared with palivizumab [86]. MedImmune recently submitted a Biologics Licence
Application but the licensing process has been delayed [87].
In addition to several promising small molecule antivirals, the exciting reports of the
remarkable effects of anti-viral siRNA seems likely to lead to improvements in treatments
for RSV infection. However, RSV infection may be difficult to control by a single drug or
monoclonal. More likely, combined therapy may be required for improved therapeutic
efficacy. For example, the synergistic action of several antibodies (e.g., the approach being
taken by Symphogen, [88]), possibly together with an antifusion drug or compound in
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combination with IMPDH inhibitor, may be required to increase treatment efficacy and at
the same time reduce the risk of emergence of resistant viral mutants.
8. Potential development issues
The very considerable and rising costs of developing effective anti-viral drugs for common
cold agents need to be viewed in the context of the normally non-life-threatening nature of
such infections. Absolute safety is paramount and is a particular concern in young children;
failure to meet stringent conditions set by licensing bodies or relatively minor commercial
setbacks may halt further development or lead to product withdrawal.
The convenience and practicality of different routes of drug delivery and the importance and
difficulty of early diagnosis are also potential limiting issues. Specifically, it seems essential
to intervene very early during infection if an anti-viral drug is to be effective. With anti-
influenza drugs, it seems that treatment needs to be given in the first 48 h of illness to be of
value. With RSV infections, it is possible that early treatment is also essential, and it may
even be optimal to start treatment even before infection becomes clinically evident to
modify disease. If this is the case, the use of anti-viral drugs would be of very limited value.
The effect of delaying treatment on efficacy needs very careful study, and the results could
have a major impact on the usefulness of therapy.
Approaches to treatment may need to be different in various target groups. For example,
long-lived passive antibody therapy may be optimal for neonates in whom vaccines may be
ineffective or dangerous and small molecule therapy impractical or potentially hazardous.
Small molecule anti-viral drugs may have a role in adults, particularly those with
immunosuppression, persistent infection or at risk of transmitting infection to susceptible
individuals. An effective vaccine could interrupt community transmission, particularly if
administered to toddlers, older children, parents and care-givers.
The fact that the epidemiology of RSV suggests community transmission can be interrupted
by variations in the weather and in social interaction and that RSV strains are specific to
narrow host range raises the exciting possibility that the combination of effective
vaccination and anti-viral therapy targeted at community sources of winter outbreaks might
conceivably lead to global elimination of RSV infection in man.
Although a distant hope, unachievable with vaccines envisaged at present and anti-viral
drugs, the prospect of eventual elimination of RSV from the human population is an
inspiring goal.
9. Expert opinion
Despite many attempts to develop vaccines and anti-viral drugs for RSV infection, treatment
remains essentially supportive at present. The remarkable success of palivizumab has
reinvigorated the field, demonstrating the potential of antibody alone to protect against RSV
infection, the great medical need and the considerable commercial opportunities in this area.
Although many anti-viral drugs fail during development, there are promising drugs in the
pipeline. It is to be hoped that one or more will be in Phase III in the near future,
establishing clinical efficacy and market niche that small molecules will occupy. Effective
and safe vaccines are keenly awaited and cheaper, longer-lasting and highly effective
antibody products are likely to continue to have a role in preventing disease, especially in
infancy. With this range of new and effective therapies, the considerable impact of RSV
infections on human health may be greatly reduced in the foreseeable future.
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Table 1
Summary of medical need.
Infants aged 2 – 8 months
during the RSV season
Passive
immunoprophylaxis;
possibly vaccines, if
immunogenic and safe
RSV-infected infants in
hospital or at home
Anti-viral drugs to limit
spread and perhaps
reduce disease severity
Care-givers of high-risk
children
Conventional vaccines
Elderly persons Vaccines and perhaps
anti-viral drugs
RSV: Respiratory syncytial virus.
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